Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have been assigned a consensus recommendation of “Hold” from the eight analysts that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $19.33.
Several equities research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. Cowen reiterated a “buy” rating on shares of Clearside Biomedical in a research report on Wednesday, October 25th. Wedbush reiterated a “buy” rating on shares of Clearside Biomedical in a research report on Wednesday, February 7th. Finally, ValuEngine lowered shares of Clearside Biomedical from a “sell” rating to a “strong sell” rating in a research report on Monday, February 5th.
Clearside Biomedical (NASDAQ:CLSD) opened at $6.44 on Tuesday. Clearside Biomedical has a 12 month low of $5.30 and a 12 month high of $10.36. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.57 and a current ratio of 4.57. The firm has a market cap of $163.21, a price-to-earnings ratio of -3.04 and a beta of -8.67.
In related news, Director Clay Thorp sold 15,000 shares of the business’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $6.37, for a total value of $95,550.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 20.90% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors lifted its holdings in Clearside Biomedical by 118.3% in the 2nd quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock valued at $107,000 after purchasing an additional 6,343 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new position in Clearside Biomedical in the 2nd quarter valued at about $122,000. Paloma Partners Management Co purchased a new position in Clearside Biomedical in the 4th quarter valued at about $124,000. The Manufacturers Life Insurance Company lifted its holdings in Clearside Biomedical by 21,620.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,811 shares of the company’s stock valued at $162,000 after purchasing an additional 17,729 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in Clearside Biomedical in the 2nd quarter valued at about $166,000. Institutional investors own 48.51% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Clearside Biomedical Inc (CLSD) Receives Consensus Recommendation of “Hold” from Analysts” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://ledgergazette.com/2018/03/14/clearside-biomedical-inc-clsd-receives-consensus-recommendation-of-hold-from-analysts.html.
About Clearside Biomedical
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.